Study of Topoisomerase Inhibition in the Treatment of Acute Leukemia
Phase 2
18 Years
60 Years
18 Years
60 Years
Not Enrolling
Both
Leukemia, Non-Hodgkin's Lymphoma
Both
Leukemia, Non-Hodgkin's Lymphoma
Trial Information
Study of Topoisomerase Inhibition in the Treatment of Acute Leukemia
Inclusion Criteria
- Patients in the following disease categories will be considered eligible for this
study: *Any acute leukemia beyond an initial attempt to induce a remission or after
relapse, *Chronic Myelogenous Leukemia in Blast Phase, *Refractory Multiple Myeloma,
*Refractory non-Hodgkin's and Hodgkin's Lymphoma
- Patients must be more than 14 days beyond prior myelotoxic chemotherapy.
- Several other eligibility criteria apply.
Type of Study:
Interventional
Study Design:
Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Authority:
United States: Federal Government
Study ID:
CADE-RCD1
NCT ID:
NCT00100477
Start Date:
December 1998
Completion Date:
Related Keywords:
- Leukemia
- Non-Hodgkin's Lymphoma
- Leukemia
- Lymphoma
- Lymphoma, Non-Hodgkin
Name | Location |
|---|---|
| Malcolm Randall VA Medical Center | Gainesville, Florida 32608 |
